All In Biotech

Drug Trial Radar · NCT05858047

An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis

A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

93

Actual

Start

Apr 11, 2023

Primary completion

Feb 21, 2024

Study completion Feb 21, 2024

Sponsor

Sponsor type
Industry
First posted
May 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.

Conditions

  • Effects, Drug Side

Interventions

  • PlaceboDrug

    Administered orally, once daily (QD)

  • SYHX1901Drug

    Administered orally, once daily (QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥75% (PASI 75) responseTime frame: Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.